Skip to main content
Article thumbnail
Location of Repository

Serum tumor markers in pediatric osteosarcoma: a summary review

By Yulia A Savitskaya, Genaro Rico-Martínez, Luis Miguel Linares-González, Ernesto Andrés Delgado-Cedillo, René Téllez-Gastelum, Alfonso Benito Alfaro-Rodríguez, Antonio Redón-Tavera and José Clemente Ibarra-Ponce de León

Abstract

Osteosarcoma is the most common primary high-grade bone tumor in both adolescents and children. Early tumor detection is key to ensuring effective treatment. Serum marker discovery and validation for pediatric osteosarcoma has accelerated in recent years, coincident with an evolving understanding of molecules and their complex interactions, and the compelling need for improved pediatric osteosarcoma outcome measures in clinical trials. This review gives a short overview of serological markers for pediatric osteosarcoma, and highlights advances in pediatric osteosarcoma-related marker research within the past year. Studies in the past year involving serum markers in patients with pediatric osteosarcoma can be assigned to one of four categories, i.e., new approaches and new markers, exploratory studies in specialized disease subsets, large cross-sectional validation studies, and longitudinal studies, with and without an intervention

Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3359274
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). A critical review of qualitative research related to children’s experiences with cancer.
    2. (2003). A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing’s sarcoma and neuroblastoma. Health Technol Assess
    3. (2011). A: Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer
    4. (2009). al: Osteosarcoma: the COSS experience. Cancer Treat Res
    5. (2010). al: Serum metallothionein in newly diagnosed patients with childhood solid tumours. Acta Biochim Pol
    6. (1996). al: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
    7. (1995). Alhava E: Multivariate analysis of six serum tumor markers (CEA,
    8. (2009). Aljubran AH: Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol
    9. (1999). AM: Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer
    10. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med
    11. (2009). Angiogenesis in pre-malignant conditions.
    12. (2001). Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost
    13. (2011). Aqeilan RI: Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.
    14. (2004). Bielack SS: Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res
    15. (1992). BN: Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer
    16. (2005). Brandlein S: The “early birds": natural IgM antibodies and immune surveillance. Histol Histopathol
    17. (2011). C: Circulating biomarker-IgM complexes in the serum of pediatric patients with osteosarcoma and Ewing’s tumor. Ann Rheum Dis
    18. (2005). Cancer in Children: Clinical Management. 5 edition.
    19. (2004). Cepulic M: Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol
    20. (2001). Chaganti RS: Cancer of the testis.
    21. (2006). Cho-Chung YS: Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta
    22. (2008). Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma.
    23. (2005). Cicognani A: Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol
    24. (1995). Clinical applications of research on angiogenesis.
    25. (2001). Clinical implications of circulating angiogenic factors in cancer patients.
    26. (2003). Dzimnaev AZ: Prognostic factors in children with osteosarcoma. Pediatric Oncology
    27. (2007). E: Molecular pathology in sarcomas. Clin Transl Oncol
    28. (1989). Eilber F: Pediatric oncology: Osteosarcoma. In Principles and Practice of Pediatric Oncology. Edited by: Pizzo PA, Poplack DG.
    29. (2004). Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem
    30. (2005). Enzyme-linked immunosorbent assay (ELISA). Clin Chem
    31. (1970). Epidemiology of bone cancer in children.
    32. (2008). et al: Cancer statistics.
    33. (2011). et al: Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer
    34. (2006). et al: Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics
    35. (2011). et al: Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer
    36. (2010). Franek E, Laskowska-Klita T: The influence of vegan diet on bone mineral density and biochemical bone turnover markers. Pediatr Endocrinol Diabetes Metab
    37. (1924). Further report of endothelial myeloma of bone.
    38. (2010). G: Osteosarcoma in very young children: experience of the Cooperative Osteosarcoma Study Group. Cancer
    39. (2011). Gołebiowska-Wawrzyniak M: Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report. Med Wieku Rozwoj
    40. (2006). Görgün O: Are serum levels of CD44 relevant in children with pediatric sarcomas? Pediatr Blood Cancer
    41. (2000). Gorlick R: Molecular pathology and molecular pharmacology of osteosarcoma. Pediatr Pathol Mol Med
    42. (1970). Hajek JV: Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases.
    43. (2000). HJ: Neoplasms of bone and soft tissue: bone tumors.
    44. (2003). JG: Serum tumor markers. Am Fam
    45. (2001). JL: Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Med Pediatr Oncol
    46. (1992). Kononenko NG: The possibilities of using the free polyamines of the peripheral blood as biochemical tumor markers in cancer children. Vopr Onkol
    47. (2000). Koops HS: Osteosarcoma of the pelvis - oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours. Eur J Surg Oncol
    48. (2006). Korzon M: Assessment of angiogenesis in children’s osteosarcoma. Med Wieku Rozwoj
    49. (2008). Krailo MD: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children’s Oncology Group. J Clin Oncol
    50. (2006). LaskowskaKlita T: Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma. Pol Merkur Lekarski
    51. (1998). Long-term results of the co-operative German-Austrian-Swiss Osteosarcoma Study Group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol
    52. (1980). MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop
    53. (1996). MA: The hazards of the biopsy, revisited.
    54. (1999). Malignant bone tumors.
    55. (2007). Markers of angiogenesis and clinical features in patients with sarcoma. Cancer
    56. (1990). Markers of central nervous system tumors. Immunol Ser
    57. (2005). Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome - the French pediatric experience. Cancer
    58. (2001). Methods Enzymol
    59. (1999). MG: Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines.
    60. (2008). MS: Circulating and imaging markers for angiogenesis. Angiogenesis
    61. (1995). Natural autoantibodies: the other side of the immune system. Res Immunol
    62. (2004). Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol
    63. (2007). Natural IgM antibodies and cancer.
    64. (2004). Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol
    65. (2006). Natural IgM antibodies: from parias to parvenus. Histol Histopathol
    66. (2005). Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol
    67. (2005). NC: Osteosarcoma of the pelvis in children and young adults: the St. Jude Children’s Research Hospital experience. Cancer
    68. (2006). Patiño-Garcia A: Bone mineral density and bone metabolism in children treated for bone sarcomas. Pediatr Res
    69. (1997). Pediatr Clin North Am
    70. (2008). Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program
    71. (2011). Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma. Tumour Biol
    72. (1958). Primary bone-forming tumours and their relationship to skeletal growth.
    73. (2004). Prognostic method for the generalisation malignant process in children with osteosarcoma. Russian Federation
    74. (1993). RCF: Serological Tumour Markers: An Introduction.
    75. (2005). Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer
    76. (2000). Role of natural and immune IgM antibodies in immune responses. Mol Immunol
    77. (1979). SA: Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer
    78. (1997). SC: PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005, 184:1293-04. Savitskaya et al. Clinical Sarcoma Research 2012, 2:9 http://www.clinicalsarcomaresearch.com/content/2/1/9 Page 8 of 995. Zhang
    79. (2003). Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.
    80. (2003). Serum levels of TNFbeta and sTNF-R in patients with malignant bone tumours. Anticancer Res
    81. (2000). Trapeznikov NN: Vascular endothelium growth factor and angiogenin in the serum of patients with osteosarcoma and Ewing’s tumor. Bull Exp Biol Med
    82. (2009). TT: Angiogenin concentration in serum of patiens with osteosarcoma: survival analysis with and without lung metastases. Vopr Onk
    83. (1991). Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma.
    84. (1985). Tumor angiogenesis. Adv Cancer Res
    85. (1995). Tumour markers: current status and future applications.
    86. (1996). Tumour markers: from laboratory to clinical use. Anticancer Res
    87. (1995). Tumour markers.
    88. (1996). Tumour size and prognosis in aggressively treated osteosarcoma.
    89. (1998). Varni JW: Effects of pediatric chronic physical disorders on child and family adjustment.
    90. (2010). Woźniak W: A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Pol Merkur Lekarski
    91. (2010). Woźniak W: Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma. Adv Med Sci

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.